Image description

Creating New HealthcareTechnologies   .  .  . 

Image description

Therapy Products


SBPL-0100


SBPL-0100 is a recombinant Measles Vaccine that kills cancer cells selectively and also delivers the genes encoding a cytokine and tumor specific antigen – both of which will help stimulate anti-tumor immunity & enhance the anti-cancer activity of SBPL-0100. Thus, SBPL-0100 combines the oncolytic effect with immunostimulating effect. SBPL is a close & improved follower of MV-NIS & MV-CEA which are undergoing Phase-I/II clinical trials as broad spectrum anticancer agents by the Mayo Clinic (USA).SBPL-0100 has shown impressive anti-cancer activity in laboratory tests and under evaluation in animal tests.


Dengue Virosomes


Dengue virosomes are non-replicating measles viruses that will express dengue virus like particles. They will synthesise Dengue virus like particles in situ after injection into human body and induce anti-dengue immunity. This project is sponsored by the Bill & Melinda Gates Foundation. If successful, it will help eliminate the need for large scale synthesis & formulation of vaccinating antigens which are critical bottleneck steps in vaccine development

Image description